Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 9, 2011, Pages 3755-3760

  Rick, Ferenc G ^a,b,c,d   Schally, Andrew V ^a,b,c   Block, Norman L ^a,b,c   Nadji, Mehrdad ^c   Szepeshazi, Karoly ^a,b   Zarandi, Marta ^a,b,c   Vidaurre, Irving ^a,b   Perez, Roberto ^a,b,c   Halmos, Gabor ^a,b,c,e   Szalontay, Luca ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b South Florida VA Foundation for Research and Education   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PÉCS   (Hungary)

^e UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Chronic prostatic inflammation; Prostatic cell death; Prostatic hypertrophy; Rodent benign prostatic hyperplasia model

Indexed keywords

CYCLOOXYGENASE 2; FINASTERIDE; GROWTH HORMONE RELEASING FACTOR ANTAGONIST; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE ANTAGONIST; INTERLEUKIN 1BETA; JMR 132; MIA 313; MIA 459; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG EFFECT; GENE EXPRESSION; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; CELL DIVISION; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-1BETA; MALE; NF-KAPPA B; ORGAN SIZE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RATS; RECEPTORS, ANDROGEN; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; SERMORELIN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

ANIMALIA; RATTUS NORVEGICUS; RODENTIA;

EID: 79952743530     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018086108     Document Type: Article

References (38)

1. Schally AV, Varga JL, Engel JB (2008) Antagonists of growth-hormone- releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4: 33-43. (Pubitemid 350291102)
2. Westley BR, May FE (1995) Insulin-like growth factors: The unrecognised oncogenes. Br J Cancer 72:1065-1066.
3. Havt A, et al. (2005) The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102:17424-17429. (Pubitemid 41740882)
4. Rekasi Z, Czompoly T, Schally AV, Halmos G (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97:10561-10566.
5. Kiaris H, Schally AV, Varga JL, Groot K, Armatis P (1999) Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma. Proc Natl Acad Sci USA 96:14894-14898. (Pubitemid 30019736)
6. Chopin LK, Herington AC (2001) A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 49:116-121. (Pubitemid 32937807)
7. Schally AV (2008) New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 40:315-322.
8. Barabutis N, Schally AV (2008) Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA 105:20470-20475.
9. Untergasser G, Madersbacher S, Berger P (2005) Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol 40:121-128. (Pubitemid 40343002)
10. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL (2003) Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 100:1250-1255. (Pubitemid 36183988)
11. Heinrich E, et al. (2008) Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 68:1763-1772.
12. Isaacs JT (1994) Etiology of benign prostatic hyperplasia. Eur Urol 25(Suppl 1):6-9.
13. Roehrborn CG (2005) Benign prostatic hyperplasia: An overview. Rev Urol 7(Suppl 9): S3-S14.
14. Coffey DS, Walsh PC (1990) Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17:461-475. (Pubitemid 20220190)
15. Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51:1202-1216.
16. Lin VK, et al. (2007) Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate 67:1265-1276. (Pubitemid 47435774)
17. Lucia MS, Lambert JR (2008) Growth factors in benign prostatic hyperplasia: Basic science implications. Curr Urol Rep 9:272-278.
18. Berger AP, et al. (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57:57-65. (Pubitemid 37070150)
19. Alonso-Magdalena P, et al. (2009) A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 106:2859-2863.
20. Maggi CA, Manzini S, Giuliani S, Meli A (1989) Infravesical outflow obstruction in rats: A comparison of two models. Gen Pharmacol 20:345-349. (Pubitemid 19093440)
21. Scolnik MD, Servadio C, Abramovici A (1994) Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl 15:287-297. (Pubitemid 24256641)
22. Liu HP, Chen GL, Liu P, Xu XP (2009) Amlodipine alone or combined with terazosin improves lower urinary tract disorder in rat models of benign prostatic hyperplasia or detrusor instability: Focus on detrusor overactivity. BJU Int 104:1752-1757.
23. Rick FG, et al. (2010) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 10.1002/pros.21289.
24. Schulz S, Röcken C, Schulz S (2006) Immunocytochemical localisation of plasma membrane GHRH receptors in human tumours using a novel anti-peptide antibody. Eur J Cancer 42:2390-2396. (Pubitemid 44307623)
25. Siejka A, Schally AV, Block NL, Barabutis N (2010) Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate 70:1087-1093.
26. Nickel JC, Downey J, Young I, Boag S (1999) Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84:976-981.
27. Tagaya M, et al. (2009) Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: A genome-wide DNA microarray analysis. Cytokine 47:185-193.
28. Steiner GE, et al. (2003) Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 83:1131-1146. (Pubitemid 37013048)
29. Vykhovanets EV, et al. (2009) Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intraprostatic inflammation. Prostate 69:633-643.
30. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071. (Pubitemid 27163860)
31. Morisset S, Patry C, Lora M, de Brum-Fernandes AJ (1998) Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 25:1146-1153. (Pubitemid 28350890)
32. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
33. Kirschenbaum A, et al. (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56:671-676.
34. Hohla F, et al. (2006) Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 103:14513-14518. (Pubitemid 44484781)
35. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501.
36. Hohla F, et al. (2009) GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 8:3149-3156.
37. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL (2004) Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Int J Cancer 112:570-576. (Pubitemid 39425936)
38. Buchholz S, et al. (2007) Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 104:1943-1946. (Pubitemid 46239883)